Pazopanib vs lapatinib
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib showed no clear difference in overall survival compared with lapatinib (low certainty).
1 finding from 1 review
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes onlyHR 0.96 [0.67, 1.38]1 study · 152 participantsLow